Term: 2010
Docket: 09-1156
Matrixx Initiatives, Inc., Et Al., Petitioners v. James Siracusano Et Al.
- Pro
09-1156 MATRIXX INITIATIVES V. SIRACUSANO DECISION BELOW: 585 F.3d 1167 CERT. GRANTED 6/14/2010 QUESTION PRESENTED: Respondents filed suit under § 10(b) of the Securities Exchange Act of 1934 and Securities and Exchange Commission Rule 10b-5, alleging that petitioners committed securities fraud by failing to disclose "adverse event" reports--i.e., reports by users of a drug that they experienced an adverse event after using the drug. The First, Second, and Third Circuits have held that drug companies have no duty to disclose adverse event reports until the reports provide statistically significant evidence that the adverse events may be caused by, and are not simply randomly associated with, a drug's use. Expressly disagreeing with those decisions, the Ninth Circuit below rejected a statistical significance standard and allowed the case to proceed despite the lack of any allegation that the undisclosed adverse event reports were statistically significant. The question presented is: Whether a plaintiff can state a claim under § 10(b) of the Securities Exchange Act and SEC Rule 10b-5 based on a pharmaceutical company's nondisclosure of adverse event reports even though the reports are not alleged to be statistically significant. LOWER COURT CASE NUMBER: 06-15677
In the case of Matrixx Initiatives, Inc., et al. v. James Siracusano et al., 2010, the U.S Supreme Court ruled in favor of shareholders who had filed a class action lawsuit against Matrixx Initiatives for failing to disclose information about adverse effects related to their leading product - Zicam Cold Remedy nasal spray and gel products. The plaintiffs claimed that Matrixx failed to inform investors about numerous reports it received indicating that Zicam could cause loss of smell (anosmia). This non-disclosure was alleged as misleading under federal securities laws since such information would have been significant for an investor's decision-making process. The court held that even though these complaints did not constitute statistically significant evidence proving causation between Zicam use and anosmia, they were still material facts which should have been disclosed by the company because reasonable investors might find them important in making investment decisions.
In the dissenting opinion for Matrixx Initiatives, Inc., et al. v. James Siracusano et al., Justice Sotomayor argued that the majority's decision to reject a statistical significance requirement in determining materiality was too broad and could lead to unnecessary litigation. She contended that not all reports of adverse events should be considered material information that companies are required to disclose under securities laws. Instead, she suggested a more nuanced approach where only credible and substantial reports would warrant disclosure, thus avoiding potential harm from false or misleading information being released into the market. Furthermore, she expressed concern over how this ruling might impact pharmaceutical companies' willingness to develop new drugs due to fear of lawsuits based on preliminary or unverified data about side effects.
